Legal Representation
Attorney
Loren R. Hulse
USPTO Deadlines
Next Deadline
1580 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240521)
Due Date
May 21, 2030
Grace Period Ends
November 21, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 21, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 21, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 5, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 5, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 14, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 14, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 31, 2024 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Jan 19, 2024 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Jan 16, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 16, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 16, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 16, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 16, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Nov 30, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 30, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 30, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 26, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 24, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Mar 24, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Dec 26, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 26, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 26, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 26, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 26, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jul 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 8, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Active chemical ingredients for use in the manufacture of anti-cancer drugs
Class 005
Anti-cancer preparations; Anti-cancer preparations of chemical origin; Anti-cancer preparations from hormones and antagonists; Anti-cancer preparations of microbial origin; Anti-cancer preparations of plant origin; Compounds for treating cancer; Pharmaceutical products for the treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Medical preparations for the treatment of cancer; Chemical preparations for medical purposes for the treatment of cancer; Biochemical preparations for medical use for the treatment of cancer; Biological preparations for medical purposes for the treatment of cancer; Anti-cancer drugs; Antitumor drugs; Injectable pharmaceuticals for the treatment of cancer; Medicinal preparations and substances for the treatment of cancer; Medicines for human purposes for the treatment of cancer; Medicines for the treatment of gastrointestinal diseases; Pharmaceutical compositions for the treatment of cancer; Pharmaceutical drugs for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for human use for the treatment of cancer; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceuticals for the treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Compounds for treating resistant cancers; Pharmaceutical preparations and substances for the treatment of treatment-resistant cancers
Class 042
Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology
Additional Information
Design Mark
The mark consists of eight turquoise dots of varying sizes arranged in a non-specific, constellation-like pattern with two large dots on the top left and two large dots along the bottom center and bottom right connected by a turquoise line.
Color Claim
The color(s) turquoise is/are claimed as a feature of the mark.
Classification
International Classes
001
005
042